In the intent-to-treat population, the median progression-free survival (PFS) was 8.77 months with giredestrant plus Afinitor ...

Adding Imfinzi (durvalumab) to Bacillus Calmette-Guérin (BCG) therapy helped patients with high-risk, non-muscle invasive ...

For patients with HRRm prostate cancer receiving Akeega and Zytiga with prednisone, quality of life remained at baseline.

Long-term follow-up of the BFR14 trial showed that Gleevec (imatinib) remains effective in advanced gastrointestinal stromal ...

Imfinzi plus FLOT chemotherapy significantly improves overall survival in resectable G/GEJ adenocarcinoma compared to placebo ...

Crawford, a medical oncologist at Duke Cancer Center and Duke Cancer Center Thoracic Clinic in Durham, North Carolina, ...

The combination of Lenvima (lenvatinib) and Keytruda (pembrolizumab) with chemotherapy did not help patients with metastatic ...

Among patients with metastatic cancer who are receiving oral targeted therapy, home-based supervised physical therapy has ...

Tagrisso combined with chemotherapy improved overall survival in EGFR-mutated NSCLC patients, including those with poor ...

Stephanie Wachtel told CURE that areola tattooing after HER2-positive breast cancer helped her feel whole again and reconnect ...

The addition of Tecentriq to BCG therapy did not significantly improve outcomes for patients with non–muscle-invasive bladder ...

Breast Cancer Awareness Month is a personal journey for survivors, emphasizing hope, connection, and shared stories. Meeting ...